Statements (59)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:pharmaceuticals
|
| gptkbp:acquisition |
gptkb:Ranbaxy_Laboratories
|
| gptkbp:annual_report |
publishes annual reports for stakeholders
|
| gptkbp:awards |
recognized for innovation in drug development
|
| gptkbp:ceo |
gptkb:J._Scott_Mc_Culloch
|
| gptkbp:clinical_trial |
conducts Phase I to Phase III trials
conducts clinical trials worldwide invests in clinical research and development |
| gptkbp:collaborations |
collaborates with academic institutions
engages in research collaborations with universities |
| gptkbp:community_engagement |
actively engages in community health programs
|
| gptkbp:conducts_research_on |
gptkb:Dr._Masato_Saito
|
| gptkbp:development |
employs a diverse global workforce
|
| gptkbp:drug_approvals |
receives drug approvals from regulatory agencies
|
| gptkbp:founded |
gptkb:2005
|
| gptkbp:founder |
gptkb:Daiichi_Pharmaceutical
|
| gptkbp:global_presence |
over 20 countries
|
| gptkbp:has_diversity_initiatives |
promotes workplace diversity
|
| gptkbp:has_research_center |
operates multiple research facilities globally
|
| gptkbp:headquarters |
gptkb:Tokyo,_Japan
|
| https://www.w3.org/2000/01/rdf-schema#label |
Daiichi Sankyo Company
|
| gptkbp:industry |
gptkb:pharmaceuticals
|
| gptkbp:innovation |
committed to innovation in healthcare.
|
| gptkbp:instruction_set |
has a robust product pipeline
|
| gptkbp:invention |
holds numerous patents in pharmaceuticals
|
| gptkbp:investment |
maintains active investor relations
invests in new drug discovery |
| gptkbp:market |
operates in global pharmaceutical market
|
| gptkbp:marketing_strategy |
develops innovative market strategies
|
| gptkbp:number_of_employees |
approximately 15,000
|
| gptkbp:partnership |
gptkb:Astra_Zeneca
gptkb:Boehringer_Ingelheim gptkb:Pfizer collaborates with biotech firms |
| gptkbp:partnerships |
forms clinical partnerships with hospitals
|
| gptkbp:philanthropy |
supports health-related charities
|
| gptkbp:products |
antibiotics
vaccines oncology drugs |
| gptkbp:regulatory_compliance |
ensures regulatory compliance in all markets
|
| gptkbp:research_areas |
focuses on multiple therapeutic areas
|
| gptkbp:research_focus |
oncology
cardiovascular diseases infectious diseases pain management |
| gptkbp:revenue |
$10 billion (2020)
|
| gptkbp:social_responsibility |
engages in community health initiatives
|
| gptkbp:stock_exchange |
gptkb:Tokyo_Stock_Exchange
|
| gptkbp:stock_symbol |
4568
|
| gptkbp:subsidiary |
gptkb:Daiichi_Sankyo,_Inc.
|
| gptkbp:sustainability_efforts |
focuses on environmental sustainability
|
| gptkbp:training |
provides extensive employee training programs
|
| gptkbp:type |
gptkb:public_company
|
| gptkbp:website |
www.daiichisankyo.com
|
| gptkbp:bfsParent |
gptkb:Daiichi_Sankyo_Foundation_of_Life_Science
gptkb:Daiichi_Sankyo_Global_Health_Foundation gptkb:Daiichi_Sankyo_Institute_of_Biomedical_Science gptkb:Daiichi_Sankyo_Research_Institute_of_Japan |
| gptkbp:bfsLayer |
7
|